The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats

Lu SongDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, People’s Republic of China

Xinxin YangDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, People’s Republic of China

Yaping MaDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, People’s Republic of China

Na WuDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, People’s Republic of China

Zhenguo LiuDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, People’s Republic of ChinaCorrespondence[email protected]

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Ana Tadijan, Ignacija Vlašić, Josipa Vlainić, Domagoj Đikić, Nada Oršolić & Maja Jazvinšćak Jembrek. (2022) Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. Antioxidants 11:10, pages 2049.
Crossref

Ivona Maria Tudorancea, Mitică Ciorpac, Gabriela Dumitrița Stanciu, Cătălin Caratașu, Alina Săcărescu, Bogdan Ignat, Alexandra Burlui, Elena Rezuș, Ioana Creangă, Teodora Alexa-Stratulat, Ionuț Tudorancea & Bogdan Ionel Tamba. (2022) The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases. Biomedicines 10:10, pages 2492.
Crossref

Xiaojie Liu, Hao Yu, Bixuan Chen, Vladislav Friedman, Lianwei Mu, Thomas J. Kelly, Gonzalo Ruiz-Pérez, Li Zhao, Xiaowen Bai, Cecilia J. Hillard & Qing-song Liu. (2022) CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice. Biomedicines 10:8, pages 1776.
Crossref

Clémence Lacroix, Isabelle Alleman-Brimault, Arnaud Zalta, Frank Rouby, Catherine Cassé-Perrot, Elisabeth Jouve, Laurence Attolini, Romain Guilhaumou, Joëlle Micallef & Olivier Blin. (2022) What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?. Frontiers in Pharmacology 13.
Crossref

Hao Yu, Xiaojie Liu, Bixuan Chen, Casey R. Vickstrom, Vladislav Friedman, Thomas J. Kelly, Xiaowen Bai, Li Zhao, Cecilia J. Hillard & Qing-Song Liu. (2021) The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson’s Disease. Cells 10:12, pages 3548.
Crossref

Tapan Behl, Gagandeep Kaur, Simona Bungau, Rishabh Jhanji, Arun Kumar, Vineet Mehta, Gokhan Zengin, Roxana Brata, Syed Shams ul Hassan & Ovidiu Fratila. (2020) Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions. International Journal of Molecular Sciences 21:17, pages 6235.
Crossref

Carla Ferreira, Catarina Almeida, Sandra Tenreiro & Alexandre Quintas. (2020) Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease. Life 10:6, pages 86.
Crossref

The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date